Anti-CTV polyclonal antibody (CABT-B1003)

Specifications


Host Species
Rabbit
Antibody Isotype
IgG
Species Reactivity
Citrus Tristeza Virus
Immunogen
A mixture of two synthetic peptides corresponding to aa 90-102 (KSSSLQSDDDATG), and aa 197-208 (KEQLLKKRGADD) of the CTV coat protein
Conjugate
Unconjugated

Applications


Application Notes
Plate-Trapped Antigen ELISA: 1:200
*Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own experiment using appropriate negative and positive controls.

Target


Alternative Names
Citrus Tristeza Virus

Citations


Have you cited CABT-B1003 in a publication? Let us know and earn a reward for your research.

Custom Antibody Labeling


We offer labeled antibodies using our catalogue antibody products and a broad range of intensely fluorescent dyes and labels including HRP, biotin, ALP, Alexa Fluor® dyes, DyLight® Fluor dyes, R-phycoerythrin (R-PE), at scales from less than 100 μg up to 1 g of IgG antibody. Learn More

Customer Reviews


Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket

References


VMAT vs Eight Field Imrt: Dosimetric Comparison of Pelvic Radiotherapy for Patients with High-Risk Prostate Cancer in Terms of Bone Marrow Sparing

TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Authors: Sezen, Duygu; Alpan, Vildan; Bolukbasi, Yasemin; Saglam, Yucel; Selek, Ugur

OBJECTIVE Although there is no complete consensus on elective pelvic nodal irradiation for patients with - risk prostate cancer, pelvic radiotherapy with androgen ablation has been more commonly used in many centers. An important part of bone marrow (BM) reserve remains in the pelvic radiation treatment field. This study aimed to evaluate and compare the intensity modulated (step-and-shoot IMRT: ssIMRT) and volumetric modulated arc radiotherapy (VMAT) techniques for pelvic radiotherapy in terms of pelvic BM doses. METHODS This study was based on the simulation scan data of 10 patients with prostate cancer as 3-mm slice thickness using a full bladder and rectal balloon. The first phase of the treatment planning prescribed to pelvic lymphatic (46 Gy/2 Gy/fraction). The second phase consisted of the seminal vesicles and prostate (32 Gy/2 Gy/fraction). The PTV margin was 0.4 cm posteriorly due to rectum and 0.6 cm in all other (including PTVlymphatic) directions. Using same target volumes, ssIMR'l with eight angles (225 degrees, 260 degrees, 295 degrees, 330 degrees, 30 degrees, 65 degrees, 100 degrees, 135 degrees) and double arc (182 degrees, -178 degrees arc angle) VMAT were planned for each patient data set. The planning objective was to cover the PTV by at least 95% of the prescribed isodose and CTV by 98% of the prescribed isodose line. No special dose constraint was given for BM sparing. Each technique was compared by using dose volume histograms (DVH) of V5, V10, V20, V30, V40 of the sacral BM (SBM), iliac BM (IBM), and ischium, pubis, and proximal femora (lower pelvis) and femoral BM (IBM). In addition, V20 V30, V40, and V70 for bladder, and V30, V40, V76, and V80 for the rectum, homogeneity index and the monitor units (MU) were evaluated. The two-sided Wilcoxon's test was used for statistical analysis (p<0.05). RESULTS For the same PTV coverage, VMAT and ssIMRT plans had similar dose distributions for FBM, IBM, SBM, and total BM as well as the other critical structures. However, VMAT plans in comparison to IMRT ensured significantly lower high dose volumes on rectum such as bringing V80 from 1.6% to 0.9% (p=0.01), and provided similar homogeneity index with lowered monitor units (1048 vs. 1591, p=0.018). CONCLUSION In this cohort, VMAT plans without a specific constraint for BM are not found to be superior to ssIMRT in terms of BM reserve irradiation; while VMAT could be encouraged for patients with higher rectum doses such as V80.

Radiation dose-painting with protons vs. photons for head-and-neck cancer

ACTA ONCOLOGICA

Authors: Hakansson, Katrin; Smulders, Bob; Specht, Lena; Zhu, Mingyao; Friborg, Jeppe; Rasmussen, Jacob H.; Bentzen, Soren M.; Vogelius, Ivan R.

Background: Dose-painting has recently been investigated in early-phase trials in head-and-neck cancer (HNC) with the aim of improving local tumor control. At the same time proton therapy has been reported as potentially capable of decreasing toxicity. Here, we investigate whether protons could be applied in a dose-painting setting by comparing proton dose distributions with delivered photon plans from a phase-I trial of FDG-PET based dose-painting at our institution. Material and methods: Eleven oropharynx (5), hypopharynx (2) and larynx cancer (4) patients from the recently conducted phase I trial were used for comparison of proton and photon dose-painting techniques. Robust optimization (3.5%/3 mm) was used for proton plans. Plan robustness and difference in dose metrics to targets and organs at risk were evaluated. Results: The proton plans met target dose constraints, while having lower non-target dose than photon plans (body-minus-CTV, mean dose 3.9 Gy vs 7.2 Gy, p = .004). Despite the use of robust proton planning for plan max dose, photon plan max doses were more robust (p = .006). Max dose to medulla, brainstem and mandible were lower in the proton plans, while there was no significant difference in mean dose to submandibular- and parotid glands. Conclusion: Proton dose-painting for HNC seems feasible and can reduce the non-target dose overall, however not significantly to certain organs close to the target, such as the salivary glands. Max dose in proton plans had a lower robustness compared to photons, requiring caution to avoid unintended hot spots in consideration of the risk of mucosal toxicity.

Online Inquiry

Name:
Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:

Related Products

Related Resources

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

Inquiry Basket